Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Pierre Delord

Showing results (21-30 of 178) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumoursPatrick Schöffski, Jean-Pierre Delord, Etienne Brain, et al.
Bulletin Du Cancer|April 6, 2013
[The management of the metastatic disease by the surgeons]Eliane Mery, Muriel Golzio, Benoît Thibault, et al.
Therapie|July 27, 2013
Drugs and cancer: an analysis of the French Pharmacovigilance DatabaseGeneviève Durrieu, Benjamin Mazau, Jérémi Jégu, et al.
Skin Appendage Disorders|February 25, 2017
Development of Photoonycholysis with Vandetanib TherapyMiruna Negulescu, Slimane Zerdoud, Serge Boulinguez, et al.
British Journal of Cancer|July 3, 2026
The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab aloneAna Cavillon, Isabelle Borget, Caroline Robert, et al.
British Journal of Cancer|September 12, 2025
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023Matthias Monnereau, Jean-Pierre Delord, Stefan Michiels, et al.
Bulletin Du Cancer|October 17, 2017
[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy]Frédéric Despiau, Yann Zagala, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Serum cystatin C is a better marker of topotecan clearance than serum creatinineAntje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, et al.
BMC Cancer|June 4, 2020
Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancerVladimir Druel, Laetitia Gimenez, Kim Paricaud, et al.
Melanoma Research|August 28, 2015
Acute skin reaction suggestive of pembrolizumab-induced radiosensitizationVincent Sibaud, Isabelle David, Laurence Lamant, et al.
Pageof 18

Showing results (21-30 of 178) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumoursPatrick Schöffski, Jean-Pierre Delord, Etienne Brain, et al.
Bulletin Du Cancer|April 6, 2013
[The management of the metastatic disease by the surgeons]Eliane Mery, Muriel Golzio, Benoît Thibault, et al.
Therapie|July 27, 2013
Drugs and cancer: an analysis of the French Pharmacovigilance DatabaseGeneviève Durrieu, Benjamin Mazau, Jérémi Jégu, et al.
Skin Appendage Disorders|February 25, 2017
Development of Photoonycholysis with Vandetanib TherapyMiruna Negulescu, Slimane Zerdoud, Serge Boulinguez, et al.
British Journal of Cancer|July 3, 2026
The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab aloneAna Cavillon, Isabelle Borget, Caroline Robert, et al.
British Journal of Cancer|September 12, 2025
Acceptance of external control arms by HTA agencies: a review of oncology submissions in France, England, Germany and Norway from 2021 to 2023Matthias Monnereau, Jean-Pierre Delord, Stefan Michiels, et al.
Bulletin Du Cancer|October 17, 2017
[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy]Frédéric Despiau, Yann Zagala, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Serum cystatin C is a better marker of topotecan clearance than serum creatinineAntje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, et al.
BMC Cancer|June 4, 2020
Improving communication between the general practitioner and the oncologist: a key role in coordinating care for patients suffering from cancerVladimir Druel, Laetitia Gimenez, Kim Paricaud, et al.
Melanoma Research|August 28, 2015
Acute skin reaction suggestive of pembrolizumab-induced radiosensitizationVincent Sibaud, Isabelle David, Laurence Lamant, et al.
Pageof 18